Conray 35 en es it fr

Conray 35 Brand names, Conray 35 Analogs

Conray 35 Brand Names Mixture

  • No information avaliable

Conray 35 Chemical_Formula


Conray 35 RX_link

No information avaliable

Conray 35 fda sheet

Conray 35 msds (material safety sheet)

Conray 35 Synthesis Reference

No information avaliable

Conray 35 Molecular Weight

241.247 g/mol

Conray 35 Melting Point

250-255 oC (hydrochloride salt)

Conray 35 H2O Solubility

>20 mg/mL (dichloride salt)

Conray 35 State


Conray 35 LogP


Conray 35 Dosage Forms

No information avaliable

Conray 35 Indication

For the treatment of tetrahydrobiopterin (BH4) deficiency.

Conray 35 Pharmacology

Tetrahydrobiopterin (BH4) is used to convert several amino acids, including phenylalanine, to other essential molecules in the body including neurotransmitters. Tetrahydrobiopterin deficiency can be caused by mutations in GTP cyclohydrolase 1 (GCH1), 6-pyruvoyl-tetrahydropterin synthase/dimerization cofactor of hepatocyte nuclear factor 1 alpha (PCBD1), 6-pyruvoyltetrahydropterin synthase (PTS), and quinoid dihydropteridine reductase (QDPR) genes. These genes make the enzymes that are critical for producing and recycling tetrahydrobiopterin. If one of the enzymes fails to function correctly because of a gene mutation, little or no tetrahydrobiopterin is produced. As a result, phenylalanine from the diet builds up in the bloodstream and other tissues and can damage nerve cells in the brain. High levels of phenylalanine can result in signs and symptoms ranging from temporary low muscle tone to mental retardation, movement disorders, difficulty swallowing, seizures, behavioral problems, progressive problems with development, and an inability to control body temperature.

Conray 35 Absorption

No information avaliable

Conray 35 side effects and Toxicity

No information avaliable

Conray 35 Patient Information

No information avaliable

Conray 35 Organisms Affected

Humans and other mammals